RT Journal Article
T1 Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study.
A1 Alcaraz, Antonio
A1 Castro-Díaz, David
A1 Gacci, Mauro
A1 Salonia, Andrea
A1 Ficarra, Vincenzo
A1 Carballido-Rodríguez, Joaquín
A1 Rodríguez-Antolín, Alfredo
A1 Medina-Polo, José
A1 Fernández-Gómez, Jesús M
A1 Cózar-Olmo, José M
A1 Búcar-Terrades, Santiago
A1 Pérez-León, Noemí
A1 Brenes-Bermúdez, Francisco J
A1 Molero-García, José M
A1 Fernández-Pro-Ledesma, Antonio
A1 Herdman, Michael
A1 Angulo, Javier C
A1 Manasanch, José
A1 On Behalf Of The Qualiprost Study Group, 
K1 5-alpha-reductase inhibitors
K1 BPH
K1 combination therapy
K1 hexanic extract of Serenoa repens
K1 moderate-severe LUTS
K1 prostate
K1 quality of life
K1 tamsulosin
K1 urinary symptoms
AB The objective of this subset analysis was to evaluate and compare the efficacy and tolerability of two combination treatments for men with moderate-to-severe lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH). Data were from a real-world, open-label, prospective, and multicenter study performed in outpatient urology clinics. Men with moderate-to-severe LUTS/BPH received 6-month treatment with tamsulosin (TAM) in combination with either the hexanic extract of S. repens (HESr) or a 5-alpha-reductase inhibitor (5ARI). Changes in urinary symptoms and quality of life were measured using the IPSS and BII questionnaires, respectively. Treatment tolerability was assessed by recording adverse effects (AEs). Patients in the two study groups were matched using iterative and propensity score matching approaches. After iterative matching, data were available from 136 patients (n = 68 treated with TAM + 5ARI, n = 68 with TAM + HESr). After 6 months of treatment, mean (SD) IPSS total score improved by 7.7 (6.3) and 6.7 (5.0) points in the TAM + 5ARI and TAM + HESr groups, respectively (p = 0.272); mean BII total scores improved by 3.1 (2.9) and 2.9 (2.4) points (p = 0.751), respectively. AEs were reported by 26.5% and 10.3% of patients in the same groups, mostly affecting sexual function (p
SN 2077-0383
YR 2022
FD 2022-06-22
LK http://hdl.handle.net/10668/21303
UL http://hdl.handle.net/10668/21303
LA en
DS RISalud
RD Apr 8, 2025